Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases

Abstract

In late December 2019, COVID-19 was firstly recognized in Wuhan, China and spread rapidly to all of the provinces of China. The West Campus of Wuhan Union Hospital, the designated hospital to admit and treat the severe and critically ill COVID-19 cases, has treated a large number of such patients with great success and obtained lots of valuable experiences based on the Chinese guideline (V7.0). To standardize and share the treatment procedures of severe and critically ill cases, Wuhan Union Hospital has established a working group and formulated an operational recommendation, including the monitoring, early warning indicators, and several treatment principles for severe and critically ill cases. The treatment experiences may provide some constructive suggestions for treating the severe and critically ill COVID-19 cases all over the world.

Keywords

2019-nCoV / COVID-19 / pneumonia / treatment / guidelines

References

[1] Wu Z, Mcgoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 2020

[2] WangDW, HuB, HuC, et al.. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069

[3] ZhouP, YangX, WangX, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798): 270-273

[4] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[5] YaoXH, LiTY, HeZC, et al.. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi (Chinese), 2020, 49(0): E009

[6] WangC, HorbyPW, HaydenFG, et al.. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223): 470-473

[7] National Health Commission. The guidelines for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection (Pilot 7rd version). [S/OL]. 2020(2020-03-03).

[8] ChenN, ZhouM, DongX, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223): 507-513

[9] CaoB, WangY, WenD, et al.. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 2020, 382(19): 1787-1799

[10] Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Int Med, 2020.

[11] DengL, LiC, ZengQ, et al.. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect, 2020, 81(1): e1-e5

[12] ZhuZ, LuZ, XuT, et al.. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect, 2020, 81(1): e21-e23

[13] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med, 2020:NEJMoa2007764

[14] GreinJ, OhmagariN, ShinD, et al.. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 2020, 382(24): 2327-2336

[15] FanE, Del SorboL, GoligherEC, et al.. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med, 2017, 195(9): 1253-1263

[16] Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives [published online ahead of print, 2020 Jun 16]. Nature, 2020:https://doi.org/10.1038/d41586-020-01824-5

[17] AbdolahiN, KahehE, GolshaR, et al.. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21(1): 549